GOLD Stage I Chronic Obstructive Pulmonary Disease (COPD)

CompletedOBSERVATIONAL
Enrollment

53

Participants

Timeline

Start Date

February 28, 2009

Study Completion Date

February 28, 2011

Conditions
Mild Chronic Obstructive Pulmonary DiseaseRespiratory SymptomsPhysical Activity
Interventions
DRUG

Combination ipratropium/salbutamol or placebo (nebulization)

The COPD patients were randomly assigned a combination of ipratropium/salbutamol or a placebo in a double-blind crossover design. The bronchodilation produced by the medication was given in order to evaluate if bronchodilation was effective in increasing exercise tolerance during an endurance shuttle walking test in patients with GOLD stage I COPD.

Trial Locations (1)

G1V 4G5

Institut universitaire de cardiologie et de pneumologie de Québec - Université Laval, Québec

Sponsors
All Listed Sponsors
collaborator

Boehringer Ingelheim

INDUSTRY

collaborator

Pfizer

INDUSTRY

lead

Laval University

OTHER